Weigh! Wu Feng, general manager of Pfizer China, leaves and Huang Hai takes over

According to internal reliable news, Michael goettler, President of Pfizer powerstrong group, sent an email to all employees announcing that Wu Feng, former general manager of Pfizer powerstrong China, was about to leave his post and look for external opportunities From now on, Huang Hai will be the chief operating officer of powerstrong China, responsible for the market and sales, reporting directly to Miao Tianxiang, President of powerstrong China In addition to the affirmation of Wu Feng's work and the expectation for the new successor, the email also mentioned the importance of the Chinese market for Pfizer It is worth mentioning that Wu Feng has worked in Pfizer for more than 22 years, during which he never skipped the slot Frank Wu, general manager of Pfizer puqiang China, joined Pfizer in 1998 He has held many senior business leadership positions in different fields of sales and marketing, including business head of chronic disease business, business head of acute disease, cardiovascular and metabolism, and CNS business Mr Wu once served as Pfizer's head of basic health China, where he managed more than $4 billion and had more than 6000 colleagues At the end of 2018, Pfizer puqiang business group focusing on chronic diseases emerged, with Wu Feng as general manager of Pfizer Upjohn in China Wu Feng established and led Pfizer China's business operations, integrating key functions such as salesperson efficiency, business analysis and insight, and sales training While leading the business and diversified businesses, he promoted the geographically expanded business group as Pfizer's strategic growth engine, as well as strengthening Pfizer's distribution network and retail business During the critical transition period, he also served as acting general manager of Pfizer China Pfizer's generic drug business, which was founded less than a year ago, will merge with Meilan, the world's largest generic drug company, to establish a new multinational pharmaceutical enterprise Pfizer shareholders will own 57% of the combined new company, while mylan shareholders will own 43% It is understood that in 2018, Pfizer's global revenue reached US $12.5 billion, including 70% of the market in developed markets in Europe and the United States, nearly 20% in China and 10% in other developing markets According to the Q1 data of Pfizer in 2019, for example, only five over 100 million varieties, many of Pfizer's sales revenue and profits come from the Chinese market Pfizer has more than 20 iconic chronic disease drugs and a leading global business model, committed to providing treatment to 225 million new patients by 2025 The Chinese market is one of the driving forces for Pfizer's continued business development As the packaging and sales segment of Pfizer's mature drugs, puqiang hopes to better adapt to the fast changing Chinese market in recent years by using the same promotion mode of mature drugs, independent of other patents and innovative drugs, so as to improve operation efficiency In May this year, Pfizer & P officially set up its global headquarters in China to protect healthy China and aspire to make China the center of global chronic disease management However, the imagination is very good, but the reality is that the countermeasures can't catch up with the policy Just three months or so after settling in Shanghai, Pfizer was revealed to be merging with mylan pharmaceutical The reason is likely to be related to the high premium of the original research drugs lost the reimbursement space due to the medical reform policies such as volume purchase Has the forecast of personnel change come true? The merger of Pfizer and mylan is regarded by the industry as a separate demand According to a headhunter, the cooperation between Pfizer and mylan is a group heating up driven by policy But whether the two sides can keep warm after holding a group depends on how to create new profit growth points with the help of each other's advantages At the same time, it points out that the merged enterprises will also face personnel changes and organizational adjustments If they fail to coordinate smoothly and make a safe transition, they will cause time and cost losses to both sides of the cooperation In my opinion, however, the price reduction policy mainly based on 4 + 7 is the biggest obstacle that leads to the over patent mature drugs When the price directly approaches the cost price, it is futile to optimize the internal The patent cliff is advancing step by step, and product stripping becomes the last choice Perhaps there are so many uncertainties that Pfizer's management will have some other ideas Of course, the author speculates that as early as last year, a large number of senior executives of foreign enterprises rushed to work in domestic innovative pharmaceutical enterprises in a high-profile way Will the general manager of puqiang China learn from Dr Wu and jump to a domestic innovation platform as an executive? We'll see At the end of this email, Michael goettler's full text is attached: Dear colleagues from puqiang China, Wu Feng will leave the post of general manager of Pfizer China to seek other opportunities Thanks to Wu Feng for his contribution to the formulation and implementation of the company's strategy and the development of the sales team in the past 22 years, especially for his successful leading of "turning point", "regional expansion" and "Navigator" projects, which have changed the lives of many Chinese patients We sincerely thank him for his important contributions to Pfizer and puqiang, and wish him greater success in his future career From now on, Huanghai will act as the chief operating officer of powerpro China, responsible for marketing and sales, and report directly to Miao Tianxiang, President of powerpro China, and the colleagues who report directly to Wu Feng will report to Huanghai Huang Hai has worked in Pfizer China for 17 years, and his performance in various positions has confirmed his leadership and strategic ability We believe that he will lead the Chinese sales and marketing team to create more brilliant There is no doubt about the importance of the Chinese market to the general strength The success of the Chinese market is essential to fulfilling our mission of reducing the burden of non communicable diseases on every thinker around the world through reliable, high-quality drugs Thank you for Qin Xian's commitment to achieve our common goals and to embody the highest ethical behavior in everything we do I believe that under the strong leadership of Miao and Huanghai, the Chinese team will continue to achieve greater success.